{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:57:26Z","timestamp":1791302246217,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Esophagectomy for esophageal cancer is associated with significant morbidity and can result in financial hardship, yet this aspect of survivorship remains understudied. This study evaluated the prevalence and risk factors of financial toxicity (FT) among patients following esophagectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who underwent esophagectomy between January 2016 and September 2022 were surveyed about demographic, financial, and employment history. Financial toxicity was measured by using the validated COST survey. Multivariate analyses identified predictors of FT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 370 patients contacted, 159 (43%) completed the survey. Median age was 65.3\u00a0years; 82.4% were male. Following therapy, 44.7% reported decreased work hours or stopped working entirely. Insurance was employer-based for 50.3%, while 40.6% had Medicare. Financial toxicity was reported by 37.1%. Risk factors included larger household size (odds ratio 2.3), low credit score (odds ratio 13.2), while high income and active retirement were protective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than a third of esophagectomy patients were found to have FT. Those with poor baseline financial health or disrupted employment were most vulnerable and may benefit from early financial counseling and support interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20623-2","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:22:19Z","timestamp":1791300139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Financial Toxicity in Patients with Resected Esophageal Cancer"],"prefix":"10.1245","author":[{"given":"Nathaniel","family":"Deboever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara B.","family":"Antonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne L.","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza J.","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle G.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara A.","family":"Vaporciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"9829","key":"20623_CR1","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/S0140-6736(12)60516-9","volume":"379","author":"SS Biere","year":"2012","unstructured":"Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, Gisbertz SS, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887\u201392.","journal-title":"Lancet."},{"issue":"11","key":"20623_CR2","doi-asserted-by":"publisher","first-page":"e030907-e","DOI":"10.1136\/bmjopen-2019-030907","volume":"9","author":"RC Brierley","year":"2019","unstructured":"Brierley RC, Gaunt D, Metcalfe C, et al. Laparoscopically assisted versus open oesophagectomy for patients with oesophageal cancer-the randomised oesophagectomy minimally invasive or open (ROMIO) study protocol for a randomised controlled trial (RCT). BMJ Open. 2019;9(11):e030907-e.","journal-title":"BMJ Open."},{"issue":"2","key":"20623_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/SLA.0000000000002171","volume":"266","author":"J Straatman","year":"2017","unstructured":"Straatman J, van der Wielen N, Cuesta MA, et al. Minimally invasive versus open esophageal resection three-year follow-up of the previously reported randomized controlled trial: the time trial. Ann Surg. 2017;266(2):232\u20136.","journal-title":"Ann Surg."},{"issue":"2","key":"20623_CR4","first-page":"153","volume":"68","author":"PM Carrera","year":"2018","unstructured":"Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153\u201365.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"20623_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jamcollsurg.2020.10.023","volume":"232","author":"CJ Coroneos","year":"2021","unstructured":"Coroneos CJ, Lin Y-L, Sidey-Gibbons C, et al. Correlation between financial toxicity, quality of life, and patient satisfaction in an insured population of breast cancer surgical patients: a single-institution retrospective study. J Am Coll Surg. 2021;232(3):253\u201363.","journal-title":"J Am Coll Surg."},{"issue":"13","key":"20623_CR6","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1002\/cncr.34220","volume":"128","author":"KL Corrigan","year":"2022","unstructured":"Corrigan KL, Fu S, Chen Y-S, et al. Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. Cancer. 2022;128(13):2455\u201362.","journal-title":"Cancer."},{"issue":"36","key":"20623_CR7","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.2217\/fon-2020-0547","volume":"16","author":"SMW Jones","year":"2020","unstructured":"Jones SMW, Henrikson NB, Panattoni L, Syrjala KL, Shankaran V. A theoretical model of financial burden after cancer diagnosis. Fut Oncol. 2020;16(36):3095\u2013105.","journal-title":"Fut Oncol."},{"issue":"1","key":"20623_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.21037\/gs.2020.03.21","volume":"10","author":"W Lane","year":"2021","unstructured":"Lane W, Phillips BT, Offodile AC. Where advocacy meets patient-centered care-cost considerations in breast reconstruction decision-making. Gland Surg. 2021;10(1):507\u201311.","journal-title":"Gland Surg."},{"issue":"6","key":"20623_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/SLA.0000000000005926","volume":"278","author":"N Deboever","year":"2023","unstructured":"Deboever N, Eisenberg M, Hofstetter W, et al. Financial toxicity in patients with resected lung cancer. Ann Surg. 2023;278(6):1038\u201344.","journal-title":"Ann Surg."},{"issue":"1","key":"20623_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.annonc.2019.10.006","volume":"31","author":"SZ Hazell","year":"2020","unstructured":"Hazell SZ, Fu W, Hu C, et al. Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life. Ann Oncol. 2020;31(1):96\u2013102.","journal-title":"Ann Oncol."},{"issue":"5","key":"20623_CR11","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1245\/s10434-020-09216-9","volume":"28","author":"AC Offodile","year":"2021","unstructured":"Offodile AC, Asaad M, Boukovalas S, et al. Financial toxicity following surgical treatment for breast cancer: a cross-sectional pilot study. Ann Surg Oncol. 2021;28(5):2451\u201362.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20623_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11701-023-01762-0","volume":"18","author":"MM Dugan","year":"2024","unstructured":"Dugan MM, Ross SB, Sucandy I, et al. Cost comparison between medicare and private insurance for robotic transhiatal esophagectomy. J Robotic Surg. 2024;18(1):30.","journal-title":"J Robotic Surg."},{"key":"20623_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.sopen.2022.05.003","volume":"9","author":"MG Park","year":"2022","unstructured":"Park MG, Haro G, Mabeza RM, et al. Association of frailty with clinical and financial outcomes of esophagectomy hospitalizations in the United States. Surg Open Sci. 2022;9:80\u20135.","journal-title":"Surg Open Sci."},{"issue":"11","key":"20623_CR14","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1007\/s11605-021-04931-4","volume":"25","author":"K Pather","year":"2021","unstructured":"Pather K, Ravindran K, Guerrier C, et al. Improved quality of care and efficiency do not always mean cost recovery after minimally invasive ivor lewis esophagectomy. J Gastrointest Surg. 2021;25(11):2742\u20139.","journal-title":"J Gastrointest Surg."},{"issue":"5","key":"20623_CR15","doi-asserted-by":"publisher","first-page":"e0285502-e","DOI":"10.1371\/journal.pone.0285502","volume":"18","author":"S Sakowitz","year":"2023","unstructured":"Sakowitz S, Mabeza RM, Bakhtiyar SS, et al. Acute clinical and financial outcomes of esophagectomy at safety-net hospitals in the United States. PloS One. 2023;18(5):e0285502-e.","journal-title":"PloS One."},{"issue":"1","key":"20623_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.amjsurg.2018.12.058","volume":"218","author":"A Wirsching","year":"2019","unstructured":"Wirsching A, Boshier PR, Krishnamoorthi R, et al. Endoscopic therapy and surveillance versus esophagectomy for early esophageal adenocarcinoma: a review of early outcomes and cost analysis. Am J Surg. 2019;218(1):164\u20139.","journal-title":"Am J Surg."},{"issue":"11","key":"20623_CR17","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1111\/ans.18062","volume":"92","author":"AF Browning","year":"2022","unstructured":"Browning AF, Chong L, Read M, Hii MW. Economic burden of complications and readmission following oesophageal cancer surgery. ANZ J Surg. 2022;92(11):2901\u20136.","journal-title":"ANZ J Surg."},{"issue":"4","key":"20623_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ejso.2016.11.013","volume":"43","author":"L Goense","year":"2017","unstructured":"Goense L, van Dijk WA, Govaert JA, van Rossum PSN, Ruurda JP, van Hillegersberg R. Hospital costs of complications after esophagectomy for cancer. Eur J Surg Oncol. 2017;43(4):696\u2013702.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"20623_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.athoracsur.2024.10.023","volume":"120","author":"AP Ng","year":"2024","unstructured":"Ng AP, Sanaiha Y, Hadaya JE, Verma A, Yanagawa J, Benharash P. Risk of financial toxicity among adults undergoing lung and esophageal resections for cancer. Ann Thorac Surg. 2024;120(2):283\u201392.","journal-title":"Ann Thorac Surg."},{"key":"20623_CR20","doi-asserted-by":"publisher","first-page":"e19406","DOI":"10.1200\/JCO.2020.38.15_suppl.e19406","volume":"38","author":"C Friedes","year":"2020","unstructured":"Friedes C, Hazell S, Fu W, et al. The evolution of financial toxicity in patients with lung cancer. J Clin Oncol. 2020;38:e19406.","journal-title":"J Clin Oncol."},{"issue":"2","key":"20623_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jtcvs.2023.05.044","volume":"167","author":"N Deboever","year":"2023","unstructured":"Deboever N, Eisenberg M, Antonoff M, et al. Perspectives, risk factors, and coping mechanisms in patients with self-reported financial burden following lung cancer surgery. J Thorac Cardiovasc Surg. 2023;167(2):478\u201387.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"5","key":"20623_CR22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/SLA.0000000000003629","volume":"271","author":"AC Offodile","year":"2020","unstructured":"Offodile AC, Hwang ES, Greenup RA. Contralateral prophylactic mastectomy in the era of financial toxicity: an additional point for concern? Ann Surg. 2020;271(5):817\u20138.","journal-title":"Ann Surg."},{"issue":"7","key":"20623_CR23","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1245\/s10434-024-15236-6","volume":"31","author":"Y Hirata","year":"2024","unstructured":"Hirata Y, To C, Lyu H, et al. Prevalence of and factors associated with financial toxicity after pancreatectomy and gastrectomy. Ann Surg Oncol. 2024;31(7):4361\u201370.","journal-title":"Ann Surg Oncol."},{"key":"20623_CR24","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1200\/JCO.2017.35.15_suppl.6615","volume":"35","author":"JA De Souza","year":"2017","unstructured":"De Souza JA, Wroblewski K, Proussaloglou E, Nicholson L, Hantel A, Wang Y. Validation of a financial toxicity (FT) grading system. J Clin Oncol. 2017;35:6615.","journal-title":"J Clin Oncol."},{"issue":"3","key":"20623_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"JA de Souza","year":"2017","unstructured":"de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the comprehensive score for financial toxicity (COST). Cancer. 2017;123(3):476\u201384.","journal-title":"Cancer."},{"issue":"1","key":"20623_CR26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1186\/s13063-022-06580-7","volume":"23","author":"VS Blinder","year":"2022","unstructured":"Blinder VS, Patil S, Finik J, et al. An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial. Trials. 2022;23(1):840.","journal-title":"Trials."},{"issue":"11","key":"20623_CR27","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/cncr.32012","volume":"125","author":"LT Dean","year":"2019","unstructured":"Dean LT, Moss SL, Rollinson SI, Frasso Jaramillo L, Paxton RJ, Owczarzak JT. Patient recommendations for reducing long-lasting economic burden after breast cancer. Cancer. 2019;125(11):1929\u201340.","journal-title":"Cancer."},{"issue":"1","key":"20623_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.athoracsur.2021.01.023","volume":"113","author":"N Panda","year":"2022","unstructured":"Panda N, Shagabayeva L, Comrie CE, et al. Drivers of cost associated with minimally invasive esophagectomy. Ann Thorac Surg. 2022;113(1):264\u201370.","journal-title":"Ann Thorac Surg."},{"key":"20623_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ygyno.2023.01.035","volume":"170","author":"MI Liang","year":"2023","unstructured":"Liang MI, Harrison R, Aviki EM, Esselen KM, Nitecki R, Meyer L. Financial toxicity: a practical review for gynecologic oncology teams to understand and address patient-level financial burdens. Gynecol Oncol. 2023;170:317\u201327.","journal-title":"Gynecol Oncol."},{"issue":"5","key":"20623_CR30","first-page":"291","volume":"15","author":"J Oh","year":"2021","unstructured":"Oh J, Ahn S. Effects of nurse navigators during the transition from cancer screening to the first treatment phase: a systematic review and meta-analysis. Asian Nurs Res (Korean Soc Nurs Sci). 2021;15(5):291\u2013302.","journal-title":"Asian Nurs Res (Korean Soc Nurs Sci)."},{"issue":"2","key":"20623_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.soncn.2013.02.005","volume":"29","author":"L McMullen","year":"2013","unstructured":"McMullen L. Oncology nurse navigators and the continuum of cancer care. Semin Oncol Nurs. 2013;29(2):105\u201317.","journal-title":"Semin Oncol Nurs."},{"issue":"7","key":"20623_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/OP.23.00680","volume":"20","author":"ER Park","year":"2024","unstructured":"Park ER, Kirchhoff AC, Donelan K, et al. Health insurance navigation tools intervention: a pilot trial within the childhood cancer survivor study. JCO Oncol Pract. 2024;20(7):953\u201363.","journal-title":"JCO Oncol Pract."},{"issue":"5","key":"20623_CR33","first-page":"437","volume":"72","author":"GL Smith","year":"2022","unstructured":"Smith GL, Banegas MP, Acquati C, et al. Navigating financial toxicity in patients with cancer: a multidisciplinary management approach. CA Cancer J Clin. 2022;72(5):437\u201353.","journal-title":"CA Cancer J Clin."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20623-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:22:21Z","timestamp":1791300141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20623-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":33,"alternative-id":["20623"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20623-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jack A. Roth: Genprex consultancy, stock, Genprex, Inc.; patents issued and pending.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}